Idorsia Ltd (IDIA)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 23 Oct 2026
Key indicators
| Last close | CHF 4.188 |
|---|---|
| 52-week range | 2.795 – 7.560 |
| Return, 1 month / 3 months | −8.3% / −31.1% |
| Return, 1 year / 3 years | +19.0% / +124.8% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 67.4% |
| Worst drawdown (1 year) | -41.5% |
| Average daily value traded | 5.82M CHF |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Idorsia Ltd is a biopharmaceutical company based in Switzerland that discovers and develops small-molecule medicines. Its main marketed product is a treatment for insomnia, and its research pipeline spans disorders of the central nervous system, the heart and blood vessels, and the immune system. The company serves patients and healthcare professionals through prescription medicines, working with partners to bring its compounds to markets in several countries.
Idorsia Ltd trades under the code IDIA on the SIX Swiss Exchange in Switzerland, with its price quoted in Swiss francs (CHF). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Idorsia Ltd (IDIA) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 4.188 on 23 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 163 of 226 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 19.0% and over the last three months it fell 31.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -8.2% | ||
| From 52-week high | -39.2% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -31.1% | ||
| 6-month return | 9.9% | ||
| 12-month return, skipping the last month | 29.8% | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 67.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.5% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 5.82M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.1% |
|---|---|
| 1 month | −8.3% |
| 3 months | −31.1% |
| 6 months | +9.9% |
| 1 year | +19.0% |
| 3 years | +124.8% |
| 5 years | −78.9% |
Signals
| 50-day / 200-day average | 4.805 / 4.561 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.204 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.